The Role of Mass Spectrometry in Hepatocellular Carcinoma Biomarker Discovery.
Metabolites
; 13(10)2023 Oct 08.
Article
in En
| MEDLINE
| ID: mdl-37887384
ABSTRACT
Hepatocellular carcinoma (HCC) is the main liver malignancy and has a high mortality rate. The discovery of novel biomarkers for early diagnosis, prognosis, and stratification purposes has the potential to alleviate its disease burden. Mass spectrometry (MS) is one of the principal technologies used in metabolomics, with different experimental methods and machine types for different phases of the biomarker discovery process. Here, we review why MS applications are useful for liver cancer, explain the MS technique, and briefly summarise recent findings from metabolomic MS studies on HCC. We also discuss the current challenges and the direction for future research.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Metabolites
Year:
2023
Document type:
Article
Affiliation country:
Taiwan